Researchers have made a discovery involving cd33 epitope editing, which may enhance the use of um171-expanded cord blood grafts. This development appears to have implications for immunotherapy, specifically in the context of aml. The breakthrough could potentially improve treatment options, although details of the discovery and its effects are not fully specified.